Mirodenafil dihydrochloride

• CAT Number: I005169
• CAS Number: 862189-96-6
• Molecular Formula: C26H39Cl2N5O5S
• Molecular Weight: 604.59
• Purity: ≥95%
• Target: Vitamin D Related/Nuclear Receptor
• Solubility: 10 mM in DMSO
• Storage: Store at -20C
• IUPAC Name: 5-ethyl-2-[5-[4-(2-hydroxyethyl)piperazin-1-yl]sulfonyl-2-propoxyphenyl]-7-propyl-3H-pyrrolo[3,2-d]pyrimidin-4-one;dihydrochloride
• InChI: InChI=1S/C26H37N5O5S.2ClH/c1-4-7-19-18-30(6-3)24-23(19)27-25(28-26(24)33)21-17-20(8-9-22(21)36-16-5-2)37(34,35)31-12-10-29(11-13-31)14-15-32;;/h8-9,17-18,32H,4-7,10-16H2,1-3H3,(H,27,28,33);2*1H
• InChIKey: CKPHITUXXABKDL-UHFFFAOYSA-N
• SMILES: CCCC1=CN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)CCO)OCCC)CC.Cl.Cl

Mirodenafil dihydrochloride（Cat No.:I005169）is a potent phosphodiesterase type 5 (PDE5) inhibitor, primarily used to treat erectile dysfunction by enhancing blood flow to the penile tissue. Similar to other PDE5 inhibitors, mirodenafil works by preventing the breakdown of cyclic GMP (cGMP), which promotes smooth muscle relaxation and vasodilation in response to sexual stimulation. Known for its rapid onset and favorable safety profile, it is especially effective for on-demand use. Mirodenafil’s action is also studied for potential applications in treating cardiovascular conditions associated with endothelial dysfunction.

Reference

[1]. Paick, J.S., et al., Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction. J Sex Med, 2008. 5(11): p. 2672-80.
[2]. Kim, B.H., et al., Influence of alcohol on the hemodynamic effects and pharmacokinetic properties of mirodenafil: a single-dose, randomized-sequence, open-label, crossover study in healthy male volunteers in Korea. Clin Ther, 2009. 31(6): p. 1234-43.
[3]. Shin, K.H., et al., The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: an open-label, one-sequence, three-period, three-treatment crossover study. Clin Ther, 2009. 31(12): p. 3009-20.